Preclinical studies identifying carboplatin as a viable cisplatin alternative

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Cisplatin is a widely used platinum-based chemotherapy agent.
• The clinical utility of cisplatin is limited by significant toxicities.
• Development of cisplatin analogues aims to improve therapeutic index.

Purpose of the Study:

• To evaluate eight cisplatin analogues as potential alternatives to cisplatin.
• To compare analogues based on toxicity, antitumour activity, and biochemical selectivity.
• To identify candidates for further clinical investigation.

Main Methods:

• Comparative analysis of preclinical data for eight platinum(II) complexes.
• Assessment of in vitro and in vivo antitumour properties.
• Evaluation of toxicological profiles and potential mechanisms of action.

Main Results:

• Significant variations in toxicity and antitumour efficacy were observed among the eight analogues.
• Diammine (1,1-cyclobutane dicarboxylato)platinum(II) (carboplatin, CBDCA, JM8) exhibited a favorable balance of reduced toxicity and potent antitumour activity.
• Other analogues showed limited advantages over cisplatin or were less effective.

Conclusions:

• Carboplatin (CBDCA, JM8) emerged as the most promising cisplatin analogue for clinical development.
• The unique chemical structure of carboplatin contributes to its improved therapeutic profile.
• Further clinical evaluation of carboplatin is warranted.